Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ConnectOne Bancorp, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Transition Period from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) Commission file number: 001-11993 OPTION CARE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 05-0489664 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 312-940-2443 Securities regis ...

PLEASANTON, Calif., February 24, 2026 – Workday, Inc. (NASDAQ: WDAY), the enterprise AI platform for managing people, money, and agents, today announced results for the fiscal 2026 fourth quarter and full year ended January 31, 2026. Fiscal 2026 Fourth Quarter Results Fiscal Year 2026 Results See the section titled "About Non-GAAP Financial Measures" in the accompanying financial tables for further details. 1 Exhibit 99.1 Workday Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results Fiscal Fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file numbe ...

Financial Results - Tempus AI, Inc. reported preliminary financial results for Q4 and full year 2025 on January 11, 2026[6] - The total remaining contract value as of December 31, 2025, was disclosed in a press release on January 11, 2026[8] Corporate Communication - The company made an updated corporate presentation available on its investor relations website on January 11, 2026[9]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 Registrant's telephone number, including area code (414) 354‑2310 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-34728 DOUGLAS DYNAMICS, INC. (Exact name of registra ...

Financial Performance - Generated $0.33 per common share of net investment income and $0.36 per share of adjusted net investment income for Q4 2025[13] - Total investment income for Q4 2024 was $56,354,000, with a net investment income of $24,171,000, representing a decrease from Q3 2025's $26,839,000[18] - The company reported a net increase in net assets resulting from operations of $17,385,000 in Q4 2025, compared to $23,903,000 in Q3 2025[18] - Net Investment Income for Q4 2025 was reported at $24,028, down from $24,171 in Q4 2024, indicating a decrease of approximately 0.6%[88] - Interest income increased from $45,697 in Q4 2024 to $60,721 in Q4 2025, representing a growth of about 32.9%[88] Portfolio and Investments - Total fair value of the portfolio increased to $2.5 billion across 165 portfolio companies with a weighted average yield of 10.1%[13] - Record originations during the quarter amounted to $404.7 million, with a weighted average yield of 8.8%[13] - New investment fundings totaled $404,746,000 in Q4 2025, with first lien debt accounting for $389,055,000 of this amount[23] - The number of investments in the portfolio was 229, with an average exposure by portfolio company of $97 million[27] - First lien debt constituted 83.7% of the total investment portfolio in Q4 2025, while second lien debt remained stable at 3.9%[20] Dividends and Shareholder Returns - Declared a quarterly dividend of $0.40 for Q1 2026, equating to an annualized dividend yield of 12.8%[13] - The annualized dividend yield to CGBD was reported at 15.3%[30] - As of Q4 2025, CGBD had an estimated $53.4 million or $0.74 per share of spillover income available to support quarterly dividends[49] - The company repurchased $13.9 million of shares in Q4, with an additional $14.0 million planned for 2026, totaling $27.9 million[49] Financial Position and Ratios - NAV per share decreased to $16.26 as of December 31, 2025, from $16.36 as of September 30, 2025[13] - Total assets increased to $2,790,167,000 in Q4 2025, up from $2,574,677,000 in Q2 2025, while total liabilities rose to $1,622,779,000[20] - The statutory debt to equity ratio increased to 1.32x in Q4 2025, reflecting a higher leverage position compared to previous quarters[20] - CGBD's net financial leverage stood at 2.89x, with an effective cost of debt of SOFR +1.60%[30] Joint Ventures and Strategic Initiatives - Entered into a new joint venture, Structured Credit Partners JV, LLC, with initial equity capital commitments of $600 million, including $150 million from Carlyle Secured Lending[16] - Structured Credit Partners JV, LLC ("SCP") is capitalized with $600 million of equity commitments from BDCs managed by Carlyle and Sixth Street[57] - SCP is expected to generate 400-500 basis points of incremental CLO return driven by no management or incentive fees at the JV or underlying CLOs[59] - Carlyle has a demonstrated track record managing CLOs over multiple credit cycles, managing $50 billion in 100+ CLOs across the U.S. and Europe[67] Asset Quality and Non-Accrual Investments - Non-accrual investments remained relatively flat at 1.8% of the total portfolio based on amortized cost as of December 31, 2025[13] - Non-accrual investments represented 1.2% of the total portfolio, indicating a stable performance in asset quality[27] - Non-accrual investments represented 1.2% of total investments at fair value, an increase from 1.0% in the prior period[43] Growth Metrics - Total Assets increased from $1,925,993 in Q4 2024 to $2,790,167 in Q4 2025, representing a growth of approximately 44.8%[86] - Total Investments at Fair Value rose from $1,803,543 in Q4 2024 to $2,463,922 in Q4 2025, an increase of about 36.6%[87] - Cash, cash equivalents, and restricted cash saw a significant increase from $56,575 in Q4 2024 to $76,493 in Q4 2025, marking a growth of 35.1%[86] - Total Liabilities increased from $1,020,789 in Q4 2024 to $1,622,779 in Q4 2025, which is an increase of approximately 59.0%[87] - Net Assets decreased from $855,204 in Q4 2024 to $1,167,388 in Q4 2025, reflecting a decline of about 36.5%[87]

MercadoLibre, Inc. Letter to Shareholders Q4'25 Results The past year showed that Mercado Libre's ecosystem is stronger than ever. Customer satisfaction reached new highs, with record Net Promoter Scores (NPS) across Commerce and Fintech in Brazil, Mexico and Argentina. This underscores the importance and effectiveness of our investments to capture structural growth opportunities across the region. Our focus on customer experience translated into strong financial performance, with revenue growth of 45% YoY ...

Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $441.1 million[5]. - OJEMDA net revenue for Q3 2025 was $38.5 million, up from $20.1 million in Q3 2024, representing a 91.5% increase[42]. - Total revenue for the nine months ended September 30, 2025, was $104.5 million, compared to $102.0 million for the same period in 2024, showing a 2.5% increase[42]. - The company reported a net loss of $19.7 million for Q3 2025, compared to a net income of $37.0 million in Q3 2024[42]. - Research and Development expenses for the nine months ended September 30, 2025, were $107.2 million, down from $165.9 million in 2024, a decrease of 35.4%[42]. - Selling, General and Administrative expenses for the nine months ended September 30, 2025, were $86.4 million, slightly up from $85.7 million in 2024[42]. Product Development and Approval - OJEMDA received FDA approval in April 2024 for pediatric patients aged 6 months and older with specific BRAF alterations[4]. - The company plans to advance the Emi-Le program with a path toward registration and has acquired Mersana Therapeutics[5]. - The pivotal Phase 3 trial of tovorafenib in front-line pediatric low-grade glioma (pLGG) is expected to complete enrollment in 1H 2026, with topline data expected mid-2027[31]. - The company plans to complete FIREFLY-2 trial enrollment in the first half of 2026, enabling mid-2027 data readout and potential approval in 2028[43]. - The company anticipates delivering Phase 1 clinical data for Emi-Le by mid-2026 and progressing to later-stage development[43]. - DAY301 is a next-generation antibody-drug conjugate (ADC) targeting PTK7, with Phase 1a data expected in 2H 2026[37]. Market Opportunity and Growth - The company aims to solidify OJEMDA as the second-line standard of care (SOC) in relapsed or refractory pediatric low-grade glioma (pLGG) and expand its market opportunity[5]. - The company anticipates a revenue opportunity exceeding $1 billion across three high unmet need indications[7]. - The number of treatment decisions for relapsed or refractory pediatric low-grade glioma (pLGG) is approximately 1,100 annually, with significant room for market share growth for OJEMDA[14]. - OJEMDA's estimated net product revenues for Q4 2025 are projected to be $52.8 million, reflecting a 37% growth compared to Q3 2025 and a 172% increase from 2024[15]. - The expected net product revenue for OJEMDA in 2026 is estimated to be between $225 million and $250 million, indicating over 50% growth compared to 2025[16]. - OJEMDA has achieved a 60% increase in 2L adoption over the past 12 months, with a growing number of healthcare providers selecting it as their treatment of choice[17]. - The company anticipates a significant increase in prescribing accounts, with 28% sequential growth in accounts treating four or more patients[18]. - OJEMDA's commercial execution is expected to drive strong growth in 2026, supported by favorable payer dynamics and a solidified position as the second-line standard of care[16]. Clinical Data and Efficacy - OJEMDA's median duration of response is reported at 19.4 months, with 77% of patients treatment-free for at least 12 months following 24 months of therapy[12]. - 75% of patients in the Expanded Access Program (EAP) who reached 24 months on OJEMDA continued treatment, demonstrating strong persistency[17]. - The Phase 2 FIREFLY-1 trial reported a 53% overall response rate (ORR) among patients, with 58% completing 26 or more treatment cycles[23]. - Median tumor size change from baseline after the last dose was -51% at 3 months and -55% at 6 months post-treatment[26]. - All 8 patients receiving OJEMDA retreatment were still on therapy at the time of data cutoff, with a median change in tumor size of -38.3%[27]. - In the updated 3-year analysis, 38 patients had RAPNO-defined progressive disease (PD) while on OJEMDA[26]. - No new safety signals were observed in the 3-year update, with 66% of treatment-related adverse events (TRAEs) being grade ≥3[29]. - 77% of 39 patients were treatment-free for at least 12 months, with the median treatment-free interval not yet reached[28]. Intellectual Property - The patent portfolio for OJEMDA includes a composition of matter patent extending to mid-2036, with additional protections potentially extending into the 2040s[20]. Strategic Partnerships - The company is focused on global commercial expansion through partnerships, including a license agreement with Ipsen for OJEMDA outside the U.S.[6]. - The company aims to expand OJEMDA globally, extending its commercial opportunity through collaboration with Ipsen[43].

Exhibit 99.1 eXp World Holdings Reports Q4 and Full-Year 2025 Results BELLINGHAM, Wash. — February 24, 2026 — eXp World Holdings, Inc. (Nasdaq: EXPI) (the "Company," "eXp" or "we"), the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. "2025 was a defining year for eXp Realty, validating our belief that transparency and agent empowerment are the only sustainable paths forward," said Leo Pare ...